Article ; Online: Disease management in a patient diagnosed with COVID-19 disease during induction intravesical BCG therapy: A case report and review of the literature.
2021 Volume 90, Issue 1, Page(s) 195–197
Abstract: Objective: To discuss the patient diagnosed with COVID-19 disease while receiving intravesical ... recommendations regarding the patient group diagnosed with COVID-19 while receiving intravesical BCG treatment ... in the light of the literature.: Patient and methods: A 52-year-old male patient, who received intravesical ...
| Abstract | Objective: To discuss the patient diagnosed with COVID-19 disease while receiving intravesical induction bacillus Calmette-Guérin (BCG) treatment for non-muscle-invasive bladder cancer, its management in the light of the literature. Patient and methods: A 52-year-old male patient, who received intravesical BCG treatment for high-grade pT1 papillary urothelial carcinoma, presented 12 h after taking the fourth dose of induction therapy 38.2° fever and chills. The patient's reverse transcriptase-polymerase chain reaction test was positive, and Thorax CT imaging showed a few ground-glass pneumonic infiltrations in bilateral lung bases consistent with COVID-19 disease. Results: Although international urology associations have current recommendations regarding the pandemic process, only one study has made specific recommendations regarding the patient group diagnosed with COVID-19 while receiving intravesical BCG treatment. According to this recommendation, we interrupted our patient's BCG treatment for 3 weeks and then completed the treatment for 6 weeks. A maintenance treatment not exceeding 1 year was planned. Conclusion: This group of patients' recommendation is to delay BCG therapy for at least 3 weeks after initial symptoms to allow for complete recovery. Although the administration schedule varies, maintenance therapy is recommended for no more than 1 year. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Male ; Middle Aged ; Adjuvants, Immunologic/therapeutic use ; Administration, Intravesical ; BCG Vaccine/therapeutic use ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/pathology ; COVID-19/diagnosis ; Disease Management ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology | |||||
| Chemical Substances | Adjuvants, Immunologic ; BCG Vaccine | |||||
| Language | English | |||||
| Publishing date | 2021-03-12 | |||||
| Publishing country | United States | |||||
| Document type | Review ; Case Reports ; Journal Article | |||||
| ZDB-ID | 204043-8 | |||||
| ISSN | 1724-6075 ; 0376-0057 ; 0391-5603 | |||||
| ISSN (online) | 1724-6075 | |||||
| ISSN | 0376-0057 ; 0391-5603 | |||||
| DOI | 10.1177/03915603211001670 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 891: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.